Circulating tumor cells (CTC) have substantial promise for multipurpose biomarker studies in prostate cancer. The IMMC-38 trial conducted by de Bono and colleagues, which was published in the October 1, 2008, issue of Clinical Cancer Research, demonstrated for the first time that CTCs are the most accurate and independent predictor of overall survival in metastatic prostate cancer.
Since the publication of prospective trials demonstrating prognostic utility, CTCs have been utilized for nucleic acid analyses, for protein analyses, and in intermediate endpoint studies. CTC studies are also now facilitating the analysis of intrapatient heterogeneity. Clin Cancer Res; 21(22); 4992-5. ©2015 AACR. See related article by de Bono et al. , Clin Cancer Res 2008;14(19) October 1, 2008;6302-9.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Nov 15 [Epub]
Niven Mehra, Zafeiris Zafeiriou, David Lorente, Leon W M M Terstappen, Johann S de Bono
Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. , Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. , Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. , Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands. , Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom.